[Standard or specific unit costs: Which criteria for choosing an economic evaluation of health strategies in multicentric studies?] |
journalArticle |
2018 |
Margier, J.; Baffert, S.; Le Corroller-Soriano, A. G. |
The cost of thromboembolic events in hospitalized patients with breast or prostate cancer in France |
journalArticle |
2015 |
Scotte, F.; Martelli, N.; Vainchtock, A.; Borget, I. |
Reply to the letter to the editor 'Ablative therapies for lung metastases: a need to acknowledge the efficacy and toxicity of stereotactic ablative body radiotherapy' by Siva et al |
journalArticle |
2015 |
de Baère, T.; Aupérin, A.; Deschamps, F.; Chevallier, P.; Gaubert, Y.; Boige, V.; Fonck, M.; Escudier, B.; Palussiére, J. |
Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab |
journalArticle |
2017 |
Chaput, N.; Lepage, P.; Coutzac, C.; Soularue, E.; Le Roux, K.; Monot, C.; Boselli, L.; Routier, E.; Cassard, L.; Collins, M.; Vaysse, T.; Marthey, L.; Eggermont, A.; Asvatourian, V.; Lanoy, E.; Mateus, C.; Robert, C.; Carbonnel, F. |
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination |
journalArticle |
2016 |
Boutros, C.; Tarhini, A.; Routier, E.; Lambotte, O.; Ladurie, F. L.; Carbonnel, F.; Izzeddine, H.; Marabelle, A.; Champiat, S.; Berdelou, A.; Lanoy, E.; Texier, M.; Libenciuc, C.; Eggermont, A. M.; Soria, J. C.; Mateus, C.; Robert, C. |
Does East meet West? Towards a unified vision of the management of Nasopharyngeal carcinoma |
journalArticle |
2019 |
Limkin, E. J.; Blanchard, P. |
Intramuscular administration of alfaxalone for sedation in rabbits |
journalArticle |
2015 |
Huynh, M.; Poumeyrol, S.; Pignon, C.; Le Teuff, G.; Zilberstein, L. |
Individualized Prediction of Menses Recovery After Chemotherapy for Early-stage Breast Cancer: A Nomogram Developed From UNICANCER PACS04 and PACS05 Trials |
journalArticle |
2018 |
Pistilli, B.; Mazouni, C.; Zingarello, A.; Faron, M.; Saghatchian, M.; Grynberg, M.; Spielmann, M.; Kerbrat, P.; Roche, H.; Lorgis, V.; Bachelot, T.; Campone, M.; Levy, C.; Goncalves, A.; Lesur, A.; Veyret, C.; Vanlemmens, L.; Lemonnier, J.; Delaloge, S. |
Variation in rates of breast cancer surgery: A national analysis based on French Hospital Episode Statistics |
journalArticle |
2016 |
Rococo, E.; Mazouni, C.; Or, Z.; Mobillion, V.; Koon Sun Pat, M.; Bonastre, J. |
Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer |
journalArticle |
2016 |
Brambilla, E.; Le Teuff, G.; Marguet, S.; Lantuejoul, S.; Dunant, A.; Graziano, S.; Pirker, R.; Douillard, J. Y.; Le Chevalier, T.; Filipits, M.; Rosell, R.; Kratzke, R.; Popper, H.; Soria, J. C.; Shepherd, F. A.; Seymour, L.; Tsao, M. S. |
Dosimetric Effects of the Interfraction Variations during Whole Breast Radiotherapy: A Prospective Study |
journalArticle |
2015 |
Jacob, J.; Heymann, S.; Borget, I.; Dumas, I.; Riahi, E.; Maroun, P.; Ezra, P.; Roberti, E.; Rivera, S.; Deutsch, E.; Bourgier, C. |
[Clinical burden caused by hospitalization for febrile neutropenia in France in 2010-2011: An analysis of the PMSI database] |
journalArticle |
2016 |
Freyer, G.; Scotte, F.; Borget, I.; Bruyas, A.; Vainchtock, A.; Chouaid, C. |
Biomarker Discovery and Validation: Statistical Considerations |
journalArticle |
2021 |
Fang-Shu Ou, PhD,a, Stefan Michiels, PhD,b Yu Shyr, PhD,c Alex A. Adjei, MD, PhD,d Ann L. Oberg, PhD |
Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status |
journalArticle |
2015 |
Messai, Y.; Gad, S.; Noman, M. Z.; Le Teuff, G.; Couve, S.; Janji, B.; Kammerer, S. F.; Rioux-Leclerc, N.; Hasmim, M.; Ferlicot, S.; Baud, V.; Mejean, A.; Mole, D. R.; Richard, S.; Eggermont, A. M.; Albiges, L.; Mami-Chouaib, F.; Escudier, B.; Chouaib, S. |
Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium |
journalArticle |
2017 |
Bautista, F.; Moreno, L.; Marshall, L.; Pearson, A. D. J.; Geoerger, B.; Paoletti, X. |
[Network meta-analyses: Interest and limits in oncology] |
journalArticle |
2016 |
Ribassin-Majed, L.; Pignon, J. P.; Michiels, S.; Blanchard, P. |
Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas |
journalArticle |
2018 |
Delahousse, J.; Verlingue, L.; Broutin, S.; Legoupil, C.; Touat, M.; Doucet, L.; Ammari, S.; Lacroix, L.; Ducreux, M.; Scoazec, J. Y.; Malka, D.; Paci, A.; Hollebecque, A. |
In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies? |
journalArticle |
2017 |
Aspeslagh, S.; Matias, M.; Palomar, V.; Dercle, L.; Lanoy, E.; Soria, J. C.; Postel-Vinay, S. |
[Reirradiation for head and neck squamous cell carcinoma: Indications and results] |
journalArticle |
2019 |
Biau, J.; Moreau, J.; Blanchard, P.; Thariat, J.; Miroir, J.; Lapeyre, M. |
Bevacizumab versus anti-epidermal growth factor receptor in first-line metastatic colorectal cancer. A meta-analysis: The last building block? |
journalArticle |
2016 |
Ducreux, M.; Pignon, J. P. |
Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries |
journalArticle |
2015 |
Cain, L. E.; Phillips, A.; Olson, A.; Sabin, C.; Jose, S.; Justice, A.; Tate, J.; Logan, R.; Robins, J. M.; Sterne, J. A.; van Sighem, A.; Reiss, P.; Young, J.; Fehr, J.; Touloumi, G.; Paparizos, V.; Esteve, A.; Casabona, J.; Monge, S.; Moreno, S.; Seng, R.; Meyer, L.; Pérez-Hoyos, S.; Muga, R.; Dabis, F.; Vandenhende, M. A.; Abgrall, S.; Costagliola, D.; Hernán, M. A. |
[Economic analysis of multinational clinical trials in oncology] |
journalArticle |
2018 |
Lejeune, C.; Lueza, B.; Bonastre, J. |
Factors which modulate the rates of skeletal muscle mass loss in non-small cell lung cancer patients: a pilot study |
journalArticle |
2017 |
Atlan, P.; Bayar, M. A.; Lanoy, E.; Besse, B.; Planchard, D.; Ramon, J.; Raynard, B.; Antoun, S. |
Establishing the Evidence Bar for Molecular Diagnostics in Personalised Cancer Care |
journalArticle |
2015 |
Schneider, D.; Bianchini, G.; Horgan, D.; Michiels, S.; Witjes, W.; Hills, R.; Plun-Favreau, J.; Brand, A.; Lawler, M. |
Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review |
journalArticle |
2015 |
Chouaïd, C.; Crequit, P.; Borget, I.; Vergnenegre, A. |
Lung Adenocarcinoma as Part of the Li-Fraumeni Syndrome Spectrum: Preliminary Data of the LIFSCREEN Randomized Clinical Trial |
journalArticle |
2017 |
Caron, O.; Frebourg, T.; Benusiglio, P. R.; Foulon, S.; Brugières, L. |
Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer |
journalArticle |
2019 |
Le Rhun, E.; Wallet, J.; Mailliez, A.; Le Deley, M. C.; Rodrigues, I.; Boulanger, T.; Lorgis, V.; Barriere, J.; Robin, Y. M.; Weller, M.; Bonneterre, J. |
Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma |
journalArticle |
2015 |
Hadoux, J.; Malka, D.; Planchard, D.; Scoazec, J. Y.; Caramella, C.; Guigay, J.; Boige, V.; Leboulleux, S.; Burtin, P.; Berdelou, A.; Loriot, Y.; Duvillard, P.; Chougnet, C. N.; Déandréis, D.; Schlumberger, M.; Borget, I.; Ducreux, M.; Baudin, E. |
[Editorial] |
journalArticle |
2018 |
Perrier, L. |
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination |
journalArticle |
2016 |
Boutros, C.; Tarhini, A.; Routier, E.; Lambotte, O.; Ladurie, F. L.; Carbonnel, F.; Izzeddine, H.; Marabelle, A.; Champiat, S.; Berdelou, A.; Lanoy, E.; Texier, M.; Libenciuc, C.; Eggermont, A. M.; Soria, J. C.; Mateus, C.; Robert, C. |
Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma |
journalArticle |
2015 |
Izzedine, H.; Derosa, L.; Le Teuff, G.; Albiges, L.; Escudier, B. |
A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, Leg Type |
journalArticle |
2018 |
Beylot-Barry, M.; Mermin, D.; Maillard, A.; Bouabdallah, R.; Bonnet, N.; Duval-Modeste, A. B.; Mortier, L.; Ingen-Housz-Oro, S.; Ram-Wolff, C.; Barete, S.; Dalle, S.; Maubec, E.; Quereux, G.; Templier, I.; Bagot, M.; Grange, F.; Joly, P.; Vergier, B.; Vially, P. J.; Gros, A.; Pham-Ledard, A.; Frison, E.; Merlio, J. P. |
Can postoperative radiotherapy be omitted in localised standard-risk Ewing sarcoma? An observational study of the Euro-E.W.I.N.G group |
journalArticle |
2016 |
Foulon, S.; Brennan, B.; Gaspar, N.; Dirksen, U.; Jeys, L.; Cassoni, A.; Claude, L.; Seddon, B.; Marec-Berard, P.; Whelan, J.; Paulussen, M.; Streitbuerger, A.; Oberlin, O.; Juergens, H.; Grimer, R.; Le Deley, M. C. |
Quality-of-Life Assessment in French Patients With Metastatic Melanoma in Real Life |
journalArticle |
2020 |
M;Kandel, S;Dalle, A;Bardet, C;Allayous, L;Mortier, C;Dutriaux, B;Guillot, M;Leccia, S;Dalac, D;Legoupil, P;Saiag, H;Montaudie, JP;Arnault, F;B.Possenti, JJ;Grob, J;DeQuatrebarbes, M;Beylot-Barry, T;Lesimple, F;Aubin, E;Maubec, F;Granel-Brocard, PE;Stoebner, A;Dupuy, B;Dreno, S;Michiels, C;Lebbe, I;Borget |
A Systematic Review of the Level of Evidence in Economic Evaluations of Medical Devices: The Example of Vertebroplasty and Kyphoplasty |
journalArticle |
2015 |
Martelli, N.; Devaux, C.; van den Brink, H.; Pineau, J.; Prognon, P.; Borget, I. |
Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door |
journalArticle |
2018 |
Verlingue, L.; Hollebecque, A.; Lacroix, L.; Postel-Vinay, S.; Varga, A.; El Dakdouki, Y.; Baldini, C.; Balheda, R.; Gazzah, A.; Michot, J. M.; Marabelle, A.; Mir, O.; Arnedos, M.; Rouleau, E.; Solary, E.; De Baere, T.; Angevin, E.; Armand, J. P.; Michiels, S.; André, F.; Deutsch, E.; Scoazec, J. Y.; Soria, J. C.; Massard, C. |
Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors |
journalArticle |
2017 |
Bahleda, R.; Le Deley, M. C.; Bernard, A.; Chaturvedi, S.; Hanley, M.; Poterie, A.; Gazzah, A.; Varga, A.; Touat, M.; Deutsch, E.; Massard, C.; Van De Velde, H.; Hollebecque, A.; Sallansonnet-Froment, M.; Ricard, D.; Taillia, H.; Angevin, E.; Ribrag, V.; Soria, J. C. |
Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours |
journalArticle |
2016 |
Gizzi, M.; Oberic, L.; Massard, C.; Poterie, A.; Gwenael, L. T.; Loriot, Y.; Albiges, L.; Baciarello, G.; Michels, J.; Bossi, A.; Blanchard, P.; Escudier, B.; Fizazi, K. |
How to Model Survival In Cost-Effectiveness Analysis? Differences Between Markov and Partitioned Survival Analysis Models |
journalArticle |
2015 |
Minacori, R.; Bonastre, J.; Lueza, B.; Marguet, S.; Levy, P. |
Antiangiogenic Tyrosine Kinase Inhibitors: Occurrence and Risk Factors of Hemoptysis in Refractory Thyroid Cancer |
journalArticle |
2016 |
Lamartina, L.; Ippolito, S.; Danis, M.; Bidault, F.; Borget, I.; Berdelou, A.; Al Ghuzlan, A.; Hartl, D.; Blanchard, P.; Terroir, M.; Deandreis, D.; Schlumberger, M.; Baudin, E.; Leboulleux, S. |